BioNTech SE (BNTX) Long-Term Debt Issuances (2018 - 2025)

BioNTech SE (BNTX) reported Long-Term Debt Issuances of $7.8 million for Q4 2025, up 3524.32% sequentially from $215188.0 in Q4 2023.

BioNTech SE (BNTX) Long-Term Debt Issuances (2018 - 2025) Analysis & Trends

BioNTech SE (BNTX) has 6 years of Long-Term Debt Issuances data on file, last reported at $7.8 million in Q4 2025.

For the quarter ending Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $7.8 million; the trailing twelve-month figure through Dec 2025 stood at $8.3 million (changed N/A YoY), and the FY2025 full-year result was $7.6 million, changed N/A from the prior year.
Long-Term Debt Issuances advanced to $7.8 million in Q4 2025, from $215188.0 in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $7.8 million in Q4 2025 to a low of $108859.0 in Q3 2023.
A 3-year average of $1.5 million and a median of $214299.7 in 2023 frame the typical range for Long-Term Debt Issuances.
Peak annual rise in Long-Term Debt Issuances reached 5.46% in 2023, while the deepest fall reached 73.01% in 2023.
Tracing BNTX's Long-Term Debt Issuances over 3 years: stood at $204049.5 in 2022, then gained by 5.46% to $215188.0 in 2023, then jumped by 3524.32% to $7.8 million in 2025.
Business Quant data shows BNTX's Long-Term Debt Issuances at $7.8 million in Q4 2025, $215188.0 in Q4 2023, and $108859.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	BioNTech SE	22.13 Bn	22.13 Bn	668.28 Mn	7.80 Mn

Download Data